603707: Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) independent directors' independent opinions on relevant matters in the 13th meeting of the Fourth Board of directors

Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) independent director

Independent opinions on matters related to the 13th meeting of the Fourth Board of directors of the company. In accordance with the guiding opinions on the establishment of independent director system in listed companies, the governance standards of listed companies, the stock listing rules of Shanghai Stock Exchange and the articles of association of Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) , we are the independent directors of Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) (hereinafter referred to as the "company"), Based on the attitude of seeking truth from facts and giving independent judgment, after reviewing relevant documents, the independent opinions on the matters considered at the 13th meeting of the Fourth Board of directors are as follows:

1、 Independent opinions on continuing to use some idle raised funds to supplement working capital temporarily

1. The company continues to use some idle raised funds to supplement working capital temporarily, which is conducive to improving the use efficiency of raised funds, reducing the company's financial expenses and safeguarding the interests of all shareholders of the company. There is no situation that damages the interests of the company and its shareholders, especially minority shareholders, The company's use of some idle raised funds to temporarily supplement working capital will not affect the normal progress of the company's fund-raising plan, and there is no behavior of changing the purpose of the raised funds in a disguised form, which is in line with the guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies The measures for the administration of raised funds of listed companies of Shanghai Stock Exchange (revised in 2013) and the measures for the administration of the use of raised funds of the company.

2. The necessary legal procedures and approval procedures have been performed for the above matters. The convening procedures and voting procedures of the board of directors comply with the provisions of relevant laws and regulations and the articles of association, and the resulting resolutions are legal and effective. In conclusion, we agree that the company will temporarily supplement the working capital with some idle raised funds of no more than RMB 300 million (including RMB 300 million), and the service life shall not exceed 12 months from the date of deliberation and approval by the board of directors.

Independent directors: Xie Shuzhi, Cui Guoqing January 11, 2022

- Advertisment -